These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28169430)

  • 61. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
    Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
    Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
    [No Abstract]   [Full Text] [Related]  

  • 62. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
    Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
    Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
    Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
    Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
    Jagannath S; Richardson PG; Barlogie B; Berenson JR; Singhal S; Irwin D; Srkalovic G; Schenkein DP; Esseltine DL; Anderson KC;
    Haematologica; 2006 Jul; 91(7):929-34. PubMed ID: 16818280
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
    Guo H; Zhou X; Jiang Y; Yang G; Sun C; Zhuang Y; Sun H; Lu M; Qian X; Chen F; Mao J; Chen H; Xia J; Shen Y
    Am J Hematol; 2010 Jul; 85(7):499-501. PubMed ID: 20575036
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J
    J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
    Goldsmith SR; Fiala MA; Wang B; Schroeder MA; Wildes TM; Ghobadi A; Stockerl-Goldstein K; Vij R
    Ann Hematol; 2020 May; 99(5):1041-1048. PubMed ID: 32130471
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
    J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.
    Mateos MV; Oriol A; Rosiñol L; de Arriba F; Puig N; Martín J; Martínez-López J; Echeveste MA; Sarrá J; Ocio E; Ramírez G; Martínez R; Palomera L; Payer A; Iglesias R; de la Rubia J; Alegre A; Chinea AI; Bladé J; Lahuerta JJ; San Miguel JF
    Haematologica; 2015 Aug; 100(8):1096-102. PubMed ID: 25911554
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
    Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Osman K; Pan S; Bhutani D; Pregja S; Sanchorawala V; Landau H
    J Clin Oncol; 2020 May; 38(13):1455-1462. PubMed ID: 32083996
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
    Gay F; Günther A; Offidani M; Engelhardt M; Salvini M; Montefusco V; Patriarca F; Aquino S; Pönisch W; Spada S; Schub N; Gentili S; Wäsch R; Corradini P; Straka C; Palumbo A; Einsele H; Boccadoro M; Sonneveld P; Gramatzki M
    Cancer; 2021 Sep; 127(18):3413-3421. PubMed ID: 34181755
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.
    Leng S; Bhutani D; Raza S; Assal A; Pan S; Hu J; Wei A; Mapara M; Lentzsch S
    Blood Cancer J; 2020 Feb; 10(2):13. PubMed ID: 32015343
    [No Abstract]   [Full Text] [Related]  

  • 75. [Clinical Study of Bortezomib in the Treatment of Multiple Myeloma at Different Dose-frequency Schedule].
    Cai DF; Sun L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Jul; 50(4):615-618. PubMed ID: 31642245
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
    Bridoux F; Arnulf B; Karlin L; Blin N; Rabot N; Macro M; Audard V; Belhadj K; Pegourie B; Gobert P; Cornec Le Gall E; Joly B; Karras A; Jaccard A; Augeul-Meunier K; Manier S; Royer B; Caillot D; Tiab M; Delbes S; Suarez F; Vigneau C; Caillard S; Arakelyan-Laboure N; Roos-Weil D; Chevret S; Fermand JP;
    J Clin Oncol; 2020 Aug; 38(23):2647-2657. PubMed ID: 32574117
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
    Ramasamy K; Iqbal G; Brouwer R; Stalker V; Akhtar S; Varghese S; Lindsay J; Schey S; Drayson M; Dunn J
    Blood Cancer J; 2022 Nov; 12(11):162. PubMed ID: 36446771
    [No Abstract]   [Full Text] [Related]  

  • 78. A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.
    Wei D; Tong Y; Bai H; Cai Q; Gao Y; Wang C
    Oncotarget; 2016 Oct; 7(43):70168-70174. PubMed ID: 27659525
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
    Lee SE; Choi K; Han S; Lee J; Hong T; Park GJ; Yim DS; Min CK
    Anticancer Drugs; 2017 Jul; 28(6):660-668. PubMed ID: 28430745
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.
    Green DJ; Bensinger WI; Holmberg LA; Gooley T; Till BG; Budde LE; Pagel JM; Frayo SL; Roden JE; Hedin L; Press OW; Gopal AK
    Bone Marrow Transplant; 2016 Oct; 51(10):1330-1336. PubMed ID: 27214069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.